Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

1. SMFM Special Statement: Checklists for preeclampsia risk-factor screening to guide recommendations for prophylactic low-dose aspirin

SMFM Special Statement: Checklists for preeclampsia risk-factor screening to guide recommendations for prophylactic low-dose aspirin Society for Maternal-Fetal Medicine Special Statement: Checklists for preeclampsia risk-factor screening to guide recommendations for prophylactic low-dose aspirin - American Journal of Obstetrics & Gynecology Go search , PB7-B11, September 01, 2020 Powered By Mendeley Share on Society for Maternal-Fetal Medicine Special Statement: Checklists for preeclampsia risk (...) -factor screening to guide recommendations for prophylactic low-dose aspirin SMFM Patient Safety and Quality Committee ∗ C. Andrew Combs Affiliations Patient Safety and Quality Improvement Committee, Society for Maternal-Fetal Medicine, Washington, DC Douglas M. Montgomery Affiliations Patient Safety and Quality Improvement Committee, Society for Maternal-Fetal Medicine, Washington, DC Published: June 14, 2020 DOI: In pregnant individuals with risk factors for preeclampsia, prophylactic low-dose

2020 Society for Maternal-Fetal Medicine

2. AORN, ASA, and APSF Clarification of Powered Air-Purifying Respirator (PAPR) Use in the Operating Room and Other Procedural Areas in Which Sterile Fields are Present

AORN, ASA, and APSF Clarification of Powered Air-Purifying Respirator (PAPR) Use in the Operating Room and Other Procedural Areas in Which Sterile Fields are Present AORN, ASA, and APSF Clarification of Powered Air-Purifying Respirator (PAPR) Use in the Operating Room and Other Procedural Areas in Which Sterile Fields are Present | American Society of Anesthesiologists (ASA) Menu Menu Close Guidelines, Statements, Clinical Resources Back Guidelines, Statements, Clinical Resources ASA Community (...) Back ASA Community Advocacy & ASAPAC Back Advocacy & ASAPAC Education and Career Back Education and Career Events Back Events In the Spotlight Back In the Spotlight Podcasts Back Podcasts Quality and Practice Management Back Quality and Practice Management Research and Publications Back Research and Publications Member Center Back Member Center About ASA Back About ASA News June 30, 2020 AORN, ASA, and APSF Clarification of Powered Air-Purifying Respirator (PAPR) Use in the Operating Room and Other

2020 American Society of Anesthesiologists

3. ASA-APSF Joint Statement on the Necessity of Wearing Face Masks in Public Full Text available with Trip Pro

ASA-APSF Joint Statement on the Necessity of Wearing Face Masks in Public ASA-APSF Joint Statement on the Necessity of Wearing Face Masks in Public Menu Menu Close Guidelines, Statements, Clinical Resources Back Guidelines, Statements, Clinical Resources ASA Community Back ASA Community Advocacy & ASAPAC Back Advocacy & ASAPAC Education and Career Back Education and Career Events Back Events In the Spotlight Back In the Spotlight Podcasts Back Podcasts Quality and Practice Management Back (...) Quality and Practice Management Research and Publications Back Research and Publications Member Center Back Member Center About ASA Back About ASA News June 30, 2020 ASA-APSF Joint Statement on the Necessity of Wearing Face Masks in Public (PDF) The American Society of Anesthesiologists (ASA) and the Anesthesia Patient Safety Foundation (APSF) strongly urge all persons over the age of 2 to cover their nose and mouth with a cloth or disposable face mask while in public. Recent studies have found

2020 American Society of Anesthesiologists

4. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis

The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y 12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard (...) navigation Circulation Actions . 2020 Aug 11;142(6):538-545. doi: 10.1161/CIRCULATIONAHA.120.046251. Epub 2020 Jun 19. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y 12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis , , Affiliations Expand Affiliation 1 TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA. PMID: 32551860 DOI: Item in Clipboard The Safety and Efficacy of Aspirin

2020 EvidenceUpdates

5. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial

Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial , , , , , , , , , , , , , Affiliations Expand Affiliations 1 School of Public Health & Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia suzanne.mahady@monash.edu. 2 Gastroenterology, Melbourne Health, Parkville, Victoria, Australia. 3 HealthPartners Institute, Minneapolis, Minnesota, USA. 4 Clinical and Translational Epidemiology Unit

2020 EvidenceUpdates

6. The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease Full Text available with Trip Pro

: 10.1161/CIR.0000000000000880. Epub 2020 Jul 6. Circulation. 2020. PMID: 32628554 No abstract available. Abstract Background: Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) but increased the risk of major bleedings. Analysis of net clinical benefit (NCB) is of key clinical relevance and represents (...) The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily

2020 EvidenceUpdates

7. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial

Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National (...) RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation JAMA Psychiatry Actions . 2020 Jun 3;e201214. doi: 10.1001/jamapsychiatry.2020.1214. Online ahead of print. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 The Institute for Mental and Physical Health and Clinical Translation Strategy Research Centre, Deakin University School of Medicine, Geelong

2020 EvidenceUpdates

8. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. (Abstract)

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with acute coronary syndromes (ACS).To determine whether switching to ticagrelor monotherapy after 3

2020 JAMA

9. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Full Text available with Trip Pro

Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled (...) into a randomised trial of daily aspirin versus placebo. This report completes the planned 10-year follow-up to allow a longer-term assessment of the effect of taking regular aspirin in this high-risk population.In the double-blind, randomised CAPP2 trial, 861 patients from 43 international centres worldwide (707 [82%] from Europe, 112 [13%] from Australasia, 38 [4%] from Africa, and four [<1%] from The Americas) with Lynch syndrome were randomly assigned to receive 600 mg aspirin daily or placebo. Cancer

2020 Lancet

10. Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline Full Text available with Trip Pro

Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline Randomized Placebo-Controlled Trial of the Effects of Aspirin on Dementia and Cognitive Decline - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology (...) Actions Cite Share Permalink Copy Page navigation Neurology Actions . 2020 Mar 25;10.1212/WNL.0000000000009277. doi: 10.1212/WNL.0000000000009277. Online ahead of print. Randomized Placebo-Controlled Trial of the Effects of Aspirin on Dementia and Cognitive Decline , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain

2020 EvidenceUpdates

11. Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention

Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health (...) Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Am Coll Cardiol Actions . 2020 May 19;75(19):2403-2413. doi: 10.1016/j.jacc.2020.03.008. Epub 2020 Mar 30. Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Cardiology, University of Florida College of Medicine

2020 EvidenceUpdates

12. Monotherapy with a P2Y<sub>12</sub> inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. (Abstract)

Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Antiplatelet therapy is recommended among patients with established atherosclerosis. We compared monotherapy with a P2Y12 inhibitor versus aspirin for secondary prevention.In this systematic review and meta-analysis, all randomised trials comparing P2Y12 inhibitor with aspirin monotherapy for secondary prevention in patients (...) determining study inclusion (ie, cerebrovascular, coronary, or peripheral artery disease), P2Y12 inhibitor type and dosage, aspirin dosage, endpoint definitions, effect estimates, follow-up duration, and percentage of patients lost to follow-up were collected. Odds ratios (ORs) and 95% CIs were used as metric of choice for treatment effects with random-effects models. Co-primary endpoints were myocardial infarction and stroke. Key secondary endpoints were all-cause death and vascular death. Heterogeneity

2020 Lancet

13. ASA/ACS/AORN/AHA Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic

ASA/ACS/AORN/AHA Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic | American Society of Anesthesiologists (ASA) Menu Menu Close Standards and Guidelines Back Standards and Guidelines Advocacy & ASAPAC Back Advocacy & ASAPAC Education and Career Back Education and Career Events Back Events In the Spotlight Back In the Spotlight Podcasts Back Podcasts Quality and Practice Management Back (...) Quality and Practice Management Research and Publications Back Research and Publications Member Center Back Member Center About ASA Back About ASA News April 17, 2020 Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic American College of Surgeons American Society of Anesthesiologists Association of periOperative Registered Nurses American Hospital Association (PDF) Introduction: In response to the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS

2020 American Society of Anesthesiologists

14. The ASA and APSF Joint Statement on Perioperative Testing for the COVID-19 Virus

The ASA and APSF Joint Statement on Perioperative Testing for the COVID-19 Virus The ASA and APSF Joint Statement on Perioperative Testing for the COVID-19 Virus | American Society of Anesthesiologists (ASA) Menu Menu Close Standards and Guidelines Back Standards and Guidelines Advocacy & ASAPAC Back Advocacy & ASAPAC Education and Career Back Education and Career Events Back Events In the Spotlight Back In the Spotlight Podcasts Back Podcasts Quality and Practice Management Back Quality (...) and Practice Management Research and Publications Back Research and Publications Member Center Back Member Center About ASA Back About ASA News April 29, 2020 The ASA and APSF Joint Statement on Perioperative Testing for the COVID-19 Virus (PDF) Patients who are infected with SARS-CoV-2, the virus responsible for the COVID-19 disease, have higher perioperative morbidity and mortality. (1-3) Unexpected progression to acute respiratory distress syndrome, cardiac injury, kidney failure and even deaths has

2020 American Society of Anesthesiologists

15. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients with Prior Percutaneous Coronary Intervention (COMPASS-PCI)

Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients with Prior Percutaneous Coronary Intervention (COMPASS-PCI) Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library (...) navigation Circulation Actions . 2020 Apr 7;141(14):1141-1151. doi: 10.1161/CIRCULATIONAHA.119.044598. Epub 2020 Mar 17. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI) , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada (K.R.B., R.C.W.). 2 Population Heath Research Institute, McMaster University and Hamilton Health Sciences, ON, Canada

2020 EvidenceUpdates

16. APSF/ASA Guidance on Purposing Anesthesia Machines as ICU Ventilators

APSF/ASA Guidance on Purposing Anesthesia Machines as ICU Ventilators APSF/ASA Guidance on Purposing Anesthesia Machines as ICU Ventilators Anesthesia machines are equipped with ventilators that in many cases are capable of providing life-sustaining mechanical ventilation to patients with respiratory failure. They are used for this purpose every day in the operating room. FDA approved labeling does not provide for using anesthesia ventilators for long term ventilatory support. Nevertheless (...) anesthesia machines safely and effectively as ICU ventilators. Detailed information is provided below and a quick reference guide is available for downloading. The quick reference guide is intended to be a bedside tool and includes a suggested schedule for monitoring the effectiveness and safety of the anesthesia ventilator. ASA is working with component societies to develop an inventory of local resources with the goal of moving machines to the locations where they are most needed. (NOTE: Local

2020 American Society of Anesthesiologists

17. Canadian Stroke Best Practice recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events

sequential analysis of randomized controlled trials. Eur Heart J 2019;40:607-17. 7. O’Brien CW, Juraschek SP, Wee CC. Prevalence of aspirin use for primary pre- vention of cardiovascular disease in the United States: results from the 2017 National Health Interview Survey. Ann Intern Med 2019 July 23 [Epub ahead of print]. doi: 10.7326/M19-0953. 8. Acetylsalicylic acid (ASA). Whitby (ON): Thrombosis Canada; 2018. Available: https://thrombosiscanada.ca/wp-content/uploads/2019/01/Acetylsalicyclic-Acid (...) % more people die of heart conditions, stroke or vascular cognitive impairment than die from all cancers combined. 1 The benefits of acetylsalicylic acid (ASA) for secondary pre- vention of atherosclerotic cardiovascular disease are well estab- lished. In contrast, although low-dose ASA therapy for primary prevention of atherosclerotic cardiovascular disease was once commonly recommended, this practice is now being recon- sidered in light of recent evidence. Three large randomized con- trolled trials

2020 CPG Infobase

18. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. (Abstract)

Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. More information is needed about the long-term effects of low-dose aspirin (≤160 mg) on incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection.Using nationwide Swedish registries, we identified all adults who received a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 2015 and who did not have (...) a history of aspirin use (50,275 patients). Patients who were starting to take low-dose aspirin (14,205 patients) were identified by their first filled prescriptions for 90 or more consecutive doses of aspirin. We constructed a propensity score and applied inverse probability of treatment weighting to balance baseline characteristics between groups. Using Cox proportional-hazards regression modeling, we estimated the risk of hepatocellular carcinoma and liver-related mortality, accounting for competing

2020 NEJM

19. Comparison of the Effect of Age (< 75 Versus >/= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneo Full Text available with Trip Pro

Comparison of the Effect of Age (< 75 Versus >/= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneo Comparison of the Effect of Age ( - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History (...) Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 10 Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden. PMID: 31924322 DOI: Item in Clipboard Full-text links Cite Abstract The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial

2020 EvidenceUpdates

20. Clopidogrel / Acetylsalicylic acid Mylan

/Acetylsalicylic acid Mylan contains two active substances, clopidogrel and acetylsalicylic acid (also known as aspirin) and is a ‘generic medicine’. This means that Clopidogrel/Acetylsalicylic acid Mylan contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called DuoPlavin. For more information on generic medicines, see the question-and-answer document here. How is Clopidogrel/Acetylsalicylic acid Mylan used? The medicine is available as tablets (...) Clopidogrel / Acetylsalicylic acid Mylan Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/628773/2019 EMEA/H/C/004996 Clopidogrel/Acetylsalicylic acid Mylan (clopidogrel

2020 European Medicines Agency - EPARs